Therapeutics News and Research

RSS

Over-the-counter insect bite remedies not very effective

Research suggests that most victims of home-bred midges, mosquitoes, flies, bedbugs and fleas will get better without any treatment at all. The review in the Drug and Therapeutics Bulletin (DTB), which offers impartial advice to doctors, admits that getting bitten may be horribly uncomfortable but there is little evidence that over-the-counter remedies work. Putting a cold compress to relieve pain and swelling could be a better option say researchers. Medical help should clearly be sought if serious symptoms, such as infections or anaphylactic shock, developed the DTB added.

12 Apr 2012

KineMed receives NIH RAID grant to advance FX-5A for heart disease

KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.

12 Apr 2012

CLYD gene serves as crucial negative regulator in pulmonary fibrosis

An international team of researchers led by Georgia State University scientists have found a key component in the pathological process of pulmonary fibrosis, a fatal disease for which there is currently no cure.

11 Apr 2012

Reducing iron levels in blood plasma may protect brain from changes related to AD

Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A new study shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.

11 Apr 2012

TCT 2012 to be held in Miami from Oct. 22-26

Media registration is now open online for TCT 2012 (Transcatheter Cardiovascular Therapeutics), the annual Scientific Symposium of the Cardiovascular Research Foundation.

10 Apr 2012

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital (MGH) researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules.

10 Apr 2012

Proteonomix provides corporate and clinical trial updates

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today provided updates on its progress.

10 Apr 2012

Researchers question wisdom of blocking DP1 in patients prone to cardiovascular disease

Niacin, or vitamin B3, is the one approved drug that elevates "good" cholesterol (high density lipoprotein, HDL) while depressing "bad" cholesterol (low density lipoprotein , LDL), and has thereby attracted much attention from patients and physicians. Niacin keeps fat from breaking down, and so obstructs the availability of LDL building blocks.

9 Apr 2012

NORD, Corcept partner to establish Cushing's Syndrome Patient Assistance Program

In partnership with Corcept Therapeutics Inc., the National Organization for Rare Disorders (NORD) has established a Cushing's Syndrome Patient Assistance Program for patients with endogenous Cushing's syndrome who need financial assistance with certain costs related to their medical diagnosis and/or care.

7 Apr 2012

Researchers generate endodermal progenitor cells for future diabetes treatments

Researchers have generated a new type of human stem cell that can develop into numerous types of specialized cells, including functioning pancreatic beta cells that produce insulin. Called endodermal progenitor (EP) cells, the new cells show two important advantages over embryonic stem cells and induced pluripotent stem cells: they do not form tumors when transplanted into animals, and they can form functional pancreatic beta cells in the laboratory.

6 Apr 2012

Zalicus' cHTS platform identifies synergistic drug combinations for treatment of cancer

Adenosine A2A and beta-2 adrenergic receptor agonists are highly synergistic and selective novel agents that enhance glucocorticoid activity in B-cell malignancies such as multiple myeloma and, importantly, can synergize in combination with current multiple myeloma treatment regimens such as melphalan, lenalidomide, bortezomib and doxorubicin.

6 Apr 2012

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease (CKD).

6 Apr 2012

Spectrum signs definitive agreement to acquire Allos

Spectrum Pharmaceuticals and Allos Therapeutics, Inc. today announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right.

6 Apr 2012

Vaccine injections given directly into pancreatic cancer tumors associated with stable disease

Research from The Cancer Institute of New Jersey (CINJ) shows that a series of vaccine injections given directly into a pancreatic cancer tumor is shown to be associated with stable disease in patients who are not candidates for surgery.

5 Apr 2012

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.

5 Apr 2012

Study assesses link between antifolate medications, KRAS mutations and amplification

Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical study presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

5 Apr 2012

CHD8, SNC2A and KATNAL2 gene mutations lead to ASDs

Mutations in three new genes have been linked to autism, according to new studies including one with investigators at Mount Sinai School of Medicine. All three studies include lead investigators of the Autism Sequencing Consortium.

5 Apr 2012

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called Accurins, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting.

5 Apr 2012

Anti-TAK1 agents may hold hope against highly aggressive KRAS mutant colon cancers

Anurag Singh, PhD, assistant professor in the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine has been invited to present his recent work on targeted therapeutics for colon cancer at the American Association of Cancer Research Annual Meeting in Chicago, IL.

4 Apr 2012

Relapse-free survival now easier to predict for several tumor stages

Researchers at Moffitt Cancer Center have carried out a study to validate the utility of new tumor classification systems for staging and predicting relapse-free survival for patients with neuroendocrine tumors (NETs) and who may be candidates for surgery.

4 Apr 2012

Therapeutics News and Research

Over-the-counter insect bite remedies not very effective

KineMed receives NIH RAID grant to advance FX-5A for heart disease

CLYD gene serves as crucial negative regulator in pulmonary fibrosis

Reducing iron levels in blood plasma may protect brain from changes related to AD

TCT 2012 to be held in Miami from Oct. 22-26

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Proteonomix provides corporate and clinical trial updates

Researchers question wisdom of blocking DP1 in patients prone to cardiovascular disease

NORD, Corcept partner to establish Cushing's Syndrome Patient Assistance Program

Researchers generate endodermal progenitor cells for future diabetes treatments

Zalicus' cHTS platform identifies synergistic drug combinations for treatment of cancer

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Spectrum signs definitive agreement to acquire Allos

Vaccine injections given directly into pancreatic cancer tumors associated with stable disease

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Study assesses link between antifolate medications, KRAS mutations and amplification

CHD8, SNC2A and KATNAL2 gene mutations lead to ASDs

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

Anti-TAK1 agents may hold hope against highly aggressive KRAS mutant colon cancers

Relapse-free survival now easier to predict for several tumor stages

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News